Type 2 diabetes, the most common form of diabetes, is characterized by abnormalities in hepatic glucose production, insulin resistance, and a progressive decline in -cell function over time. To treat effectively the individual with type 2 diabetes, the provider must have a thorough understanding of the underlying pathophysiology to provide treatment that precisely addresses the metabolic abnormalities. Currently, the provider who cares for subjects with type 2 diabetes can choose an antidiabetic agent from no less than eight pharmacologic classes. These classes include agents that increase insulin secretion, improve insulin action, and delay absorption of carbohydrates. The newer treatments available, specifically incretin therapy, address a previously unmet need in diabetes by modulating glucose supply. The currently available agents can be combined and combination therapy markedly improves glycemic control. This allows the provider to design regimens to specifically address underlying abnormalities.
Goals
A1c goal recommended by the American Diabetes Association (ADA) is a A1c value <7%. This is not a value considered in the normal range, as an A1c level of 4.0–6.0% is considered as the non-diabetic range. However, this level was selected on the basis of practicality and the projected reduction in complications over time. The ADA guidelines also suggest that for "the individual patient," the A1c should be "as close to normal (<6%) as possible without significant hypoglycemia". The most recent glycemic goal set by both the American Association of Clinical Endocrinologists and the European Union–International Diabetes Federation is an A1c level <6.5%.
Tuesday, May 27, 2008
Subscribe to:
Post Comments (Atom)
Free Books, powerpoint presentations, teaching tools and resources and drug information
-
-
Is Vitapulse a Scam? - The heart is a vital organ of the body and it plays major roles in its general functioning. Proper healthcare should be taken to ensure the heart functio...8 years ago
-
Comparative Effect of Agomelatine versus Escitalopram on Glycemic Control and Symptoms of Depression in Patients with Type 2 Diabetes Mellitus and Depression - Kumar K, Salman MT, Shukla V, Ahmad A, Verma V K, Rizvi D A and Kohli A: Comparative Effect of Agomelatine versus Escitalopram on Glycemic Control and Symp...8 years ago
-
Ranking of Indian Repositories - Ranking of Indian Repositories based on Ranking of Web of World Repositories, January 2009 Edition. World Ranking among all types of Repositories ...15 years ago
-
For Computer-lOvErS - *Antivirus SofTwArEs* Norton 360 (Up To 12 Years Key) Norton AntiVirus 2008 AVG Antivirus Panda.Antivirus NOD32 Antivirus Kingsoft Antivirus Kaspersky...15 years ago
-
Contemporary Targeted Therapies in Rheumatology - Publisher: Informa Healthcare Number Of Pages: 636 Publication Date: 2007-10-24 ISBN-10 / ASIN: 1841844845 ISBN-13 / EAN: 9781841844848 Binding: Hardcover ...15 years ago
-
-
-
-
-
-
-
No comments:
Post a Comment
Add your comment